Edwards Lifesciences Sees Q3 Adj. EPS $0.80-$0.90 vs $0.83 Est., Sales $810M-$850M vs $824.73M Est.; FY17 Adj. EPS Guidance Raised From $3.43-$3.55 To $3.65-$3.85 vs $3.53 Est., Sales $3.2B-$3.4B vs $3.35B Est.